Market revenue in 2023 | USD 2,391.6 million |
Market revenue in 2030 | USD 4,210.9 million |
Growth rate | 8.4% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 84.71% in 2023. Horizon Databook has segmented the North America hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
North America accounted for a substantial revenue share in 2020, owing to continuous development of hereditary genetic testing solutions by key vendors. For instance, in August 2018, LabCorp’s company Dynacare entered into an agreement with London Health Sciences Centre to conduct genetic testing for Charcot-Marie-Tooth disease, mitochondrial disorders, and epilepsy at its genetics laboratory in Canada.
Dynacare gained exclusive rights to provide multi-gene panel tests to patients throughout the U.S. and a few parts of Canada. Similarly, in September 2019, Finnish company Blueprint Genetics partnered with ARCHIMEDlife, a rare disease diagnostics company, to provide biochemical testing for rare diseases in North America.
Through the partnership, both firms planned to diversify their range of genetic disease testing services to better serve North American customers. Similar initiatives are expected to strengthen genetic testing scenario for hereditary disorders in North America, thereby accelerating regional revenue generation.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America hereditary testing market, including forecasts for subscribers. This continent databook contains high-level insights into North America hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account